Form D · Biotechnology
PERFUSIX USA, Inc.
Greenwood Village, CO · CIK 0001577439
Offering snapshot reported May 22, 2013 · SEC filing
- Reported sold
- $800K Offering amount: $800K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 10, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 22, 2013 | Initial | $800,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-196881
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| N/A | None |
Source: Form D, filed May 22, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Marcelo Cypel | Director |
| James Edgemond | Director |
| Chris Jaynes | Director, Executive |
| Shaf Keshavjee | Director, Executive |
| Tim Klug | Director, Executive |
| Tom Waddell | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
8547 E Arapahoe Rd, Suite J 448
Greenwood Village, CO, 80112
Greenwood Village, CO, 80112